Eli Lilly Secures $2.75B Deal With Insilico for AI-Developed Drugs – An Industry Game-Changer

In a landmark event for the pharmaceutical industry, Eli Lilly and Company has secured a $2.75 billion deal with Insilico Medicine. This agreement positions the Indianapolis-based pharmaceutical company at the cutting-edge of artificial intelligence-aided drug discovery.nnThe deal leverages Insilico’s deep learning and AI technologies to boost drug discovery and development. The partnership guarantees Eli Lilly’s access to potentially game-changing therapies, ensuring customer-centric innovation and continued leadership in the global healthcare sector.nn Read More